Trial Profile

Transplantation of haploidentical CD34+ purified peripheral blood stem cells with NK [natural killer]-cell add-back following conditioning with total body irradiation, thiotepa, fludarabine and OKT3 [muromonab-CD3].

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Muromonab CD3 (Primary) ; Natural killer cell therapy (Primary) ; Fludarabine; Methotrexate; Thiotepa
Indications Graft-versus-host disease; Leukaemia
Focus Therapeutic Use

24 May 2017 Biomarkers information updated
24 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
24 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com